Clinical trial / 2008
Water-gargling was suggested to be a cost-effective strategy for preventing upper respiratory tract infections from a societal perspective.
An economic evaluation alongside a randomized controlled trial evaluated the cost-effectiveness of water-gargling versus control for preventing upper respiratory tract infections (URTI) over 60 days. The water-gargling group had a 0.43 increase in quality-adjusted life days (QALD) and $37.1 higher costs, yielding an incremental cost-effectiveness ratio (ICER) of $31,800 per QALY (95% CI, $1,900-$248,100). The authors note that the broad confidence interval indicates uncertainty, and a major limitation is that the trial was conducted in winter when URTI is prevalent, which may limit generalizability to other seasons.
- Study type
- Economic evaluation alongside a randomized controlled trial
- Who was studied
- 122 water-gargling and 130 control subjects
- What was measured
- 60-day cumulative follow-up costs, quality-adjusted life days (QALD), and ICER
THE PAPER
Cost-effectiveness of gargling for the prevention of upper respiratory tract infections.
Sakai M, Shimbo T, Omata K, Takahashi Y, Satomura K, Kitamura T, Kawamura T, Baba H, Yoshihara M, Itoh H, Great Cold Investigators-I. BMC Health Serv Res, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.